Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names. The company was founded in 1936 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for FDC
Revenue projections for FDC



Financial Ratios:

currentRatio 0.00000
forwardPE 0.00000
debtToEquity 0.87800
earningsGrowth -0.53100
revenueGrowth 0.01300
grossMargins 0.63295
operatingMargins 0.07174
trailingEps 16.73000
forwardEps 23.30000

With both earnings and revenue growth in low territory, FDC is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
FDC Limited's negative gross and operating margins suggest that the company is currently losing money, unable to generate profit from production or operations. This could signal inefficiencies in cost control or a drop in sales.
FDC's forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with FDC anticipated to deliver better earnings than it did in the prior year.

Recommendation changes over time:

Recommendations trend for FDC
Recommendations trend for FDC


Analysts have shown a buy bias for FDC, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to FDC, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.